Skip to main content
Journal cover image

Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.

Publication ,  Journal Article
Lawson, JH; Glickman, MH; Ilzecki, M; Jakimowicz, T; Jaroszynski, A; Peden, EK; Pilgrim, AJ; Prichard, HL; Guziewicz, M; Przywara, S; Szmidt, J ...
Published in: Lancet
May 14, 2016

BACKGROUND: For patients with end-stage renal disease who are not candidates for fistula, dialysis access grafts are the best option for chronic haemodialysis. However, polytetrafluoroethylene arteriovenous grafts are prone to thrombosis, infection, and intimal hyperplasia at the venous anastomosis. We developed and tested a bioengineered human acellular vessel as a potential solution to these limitations in dialysis access. METHODS: We did two single-arm phase 2 trials at six centres in the USA and Poland. We enrolled adults with end-stage renal disease. A novel bioengineered human acellular vessel was implanted into the arms of patients for haemodialysis access. Primary endpoints were safety (freedom from immune response or infection, aneurysm, or mechanical failure, and incidence of adverse events), and efficacy as assessed by primary, primary assisted, and secondary patencies at 6 months. All patients were followed up for at least 1 year, or had a censoring event. These trials are registered with ClinicalTrials.gov, NCT01744418 and NCT01840956. FINDINGS: Human acellular vessels were implanted into 60 patients. Mean follow-up was 16 months (SD 7·6). One vessel became infected during 82 patient-years of follow-up. The vessels had no dilatation and rarely had post-cannulation bleeding. At 6 months, 63% (95% CI 47-72) of patients had primary patency, 73% (57-81) had primary assisted patency, and 97% (85-98) had secondary patency, with most loss of primary patency because of thrombosis. At 12 months, 28% (17-40) had primary patency, 38% (26-51) had primary assisted patency, and 89% (74-93) had secondary patency. INTERPRETATION: Bioengineered human acellular vessels seem to provide safe and functional haemodialysis access, and warrant further study in randomised controlled trials. FUNDING: Humacyte and US National Institutes of Health.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

May 14, 2016

Volume

387

Issue

10032

Start / End Page

2026 / 2034

Location

England

Related Subject Headings

  • Vascular Access Devices
  • Renal Dialysis
  • Prosthesis Design
  • Polytetrafluoroethylene
  • Muscle, Smooth, Vascular
  • Middle Aged
  • Male
  • Kidney Failure, Chronic
  • Humans
  • Graft Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lawson, J. H., Glickman, M. H., Ilzecki, M., Jakimowicz, T., Jaroszynski, A., Peden, E. K., … Niklason, L. E. (2016). Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet, 387(10032), 2026–2034. https://doi.org/10.1016/S0140-6736(16)00557-2
Lawson, Jeffrey H., Marc H. Glickman, Marek Ilzecki, Tomasz Jakimowicz, Andrzej Jaroszynski, Eric K. Peden, Alison J. Pilgrim, et al. “Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.Lancet 387, no. 10032 (May 14, 2016): 2026–34. https://doi.org/10.1016/S0140-6736(16)00557-2.
Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, et al. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet. 2016 May 14;387(10032):2026–34.
Lawson, Jeffrey H., et al. “Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.Lancet, vol. 387, no. 10032, May 2016, pp. 2026–34. Pubmed, doi:10.1016/S0140-6736(16)00557-2.
Lawson JH, Glickman MH, Ilzecki M, Jakimowicz T, Jaroszynski A, Peden EK, Pilgrim AJ, Prichard HL, Guziewicz M, Przywara S, Szmidt J, Turek J, Witkiewicz W, Zapotoczny N, Zubilewicz T, Niklason LE. Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials. Lancet. 2016 May 14;387(10032):2026–2034.
Journal cover image

Published In

Lancet

DOI

EISSN

1474-547X

Publication Date

May 14, 2016

Volume

387

Issue

10032

Start / End Page

2026 / 2034

Location

England

Related Subject Headings

  • Vascular Access Devices
  • Renal Dialysis
  • Prosthesis Design
  • Polytetrafluoroethylene
  • Muscle, Smooth, Vascular
  • Middle Aged
  • Male
  • Kidney Failure, Chronic
  • Humans
  • Graft Survival